PROCEPT BioRobotics Corp (PRCT) stock falls 3.23% on July 21

Shares of PROCEPT BioRobotics Corp (PRCT) fell 3.23% on Jul 21, reaching an intraday low of $56.37. The stock is currently 45.61% below its 52-week high of $103.81 and 20.04% above its 52-week low of $47.04. Analysts forecast an average target price of $77.20, with an upside of 36.72% from the current price. The estimated GF Value for PRCT is $137.07, suggesting a 142.74% upside from the current price.

Shares of PROCEPT BioRobotics Corp (PRCT) fell 3.23% on July 21, reaching an intraday low of $56.37. The stock is currently trading 45.61% below its 52-week high of $103.81 and 20.04% above its 52-week low of $47.04. Analysts forecast an average target price of $77.20, with an upside of 36.72% from the current price. The estimated GF Value for PRCT is $137.07, suggesting a 142.74% upside from the current price.

Morgan Stanley recently revised its price target for PROCEPT BioRobotics from $71 to $68, maintaining an Overweight rating on the company's shares. The analyst noted that the MedTech industry is showing stability in terms of procedure volumes and hospital capital expenditures, supporting a positive outlook for PROCEPT BioRobotics within the sector [1].

On July 18, PROCEPT BioRobotics shares surged 3.68% to an intraday high of $62.17, settling at $61.10. The stock is currently 41.14% below its 52-week high and 29.89% above its 52-week low. Analysts forecast an average target price of $77.20, with a high estimate of $90.00 and a low estimate of $60.00, implying an upside of 26.35% from the current price. The estimated GF Value for PRCT in one year is $137.07, suggesting a 124.34% upside from the current price [2].

PROCEPT BioRobotics announced that its Aquablation therapy has been assigned a Category I Current Procedural Terminology (CPT) code, effective January 1, 2026. This development supports broader patient access and surgeon adoption, potentially becoming the standard of care for benign prostatic hyperplasia (BPH) treatment. The new code replaces the previous Category III code, indicating a favorable reimbursement landscape for Aquablation therapy [3].

Investors should monitor the public comment period and final rule announcement for any changes that could impact market dynamics. The potential risks associated with the proposed rule include the possibility of changes following the public comment period and the inherent side effects of surgical treatments.

The stock price surge on July 18 reflected investors' optimism about the potential growth prospects of PROCEPT BioRobotics following the CPT code assignment. The company's stock price is currently trading at a discount compared to its 52-week high, with analysts forecasting a significant upside potential.

References:
[1] https://www.gurufocus.com/news/2976934/procept-biorobotics-prct-sees-price-target-adjustment-by-morgan-stanley-prct-stock-news
[2] https://www.ainvest.com/news/procept-biorobotics-corp-shares-surge-3-68-analyst-predictions-26-35-upside-2507/
[3] https://www.nasdaq.com/articles/procept-biorobotics-announces-category-i-cpt-code-assignment-aquablation-therapy-effective